Limited utility of conventional criteria for predicting unresectable disease in patients with advanced stage epithelial ovarian cancer

Gynecologic Oncology

Volumn 108, Issue 2, 2008, Pages 271-275

  Salani, Ritu ^a   Axtell, Allison ^b,c   Gerardi, Melissa ^a   Holschneider, Christine ^c   Bristow, Robert E ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c OLIVE VIEW UCLA MEDICAL CENTER   (United States)

Author keywords

Cytoreductive surgery; Ovarian cancer; Unresectable disease

Indexed keywords

ADULT; ADVANCED CANCER; ANALYTIC METHOD; ARTICLE; ASCITES; CANCER SURGERY; CARCINOMATOSIS; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; FEMALE; HUMAN; LIVER HILUS; LIVER PARENCHYMA; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MEDICAL RECORD; OVARY CANCER; PATIENT REFERRAL; PREDICTION AND FORECASTING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPLEEN;

EPITHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS;

EID: 38649109134     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.11.004     Document Type: Article

References (33)

1. IARC. GLOBOCAN. Cancer Incidence, Mortality and Prevalence Worldwide (2002 Estimates) (2002). http://www-dep.iarc.fr/ Available at URL: http://www-dep.iarc.fr/ Accessed 2007
2. Chi D.S., Liao J.B., Leon L.F., Venkatraman E.S., Hensley M.L., Bhaskaran D., and Hoskins W.J. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82 3 (2001) 532-537
3. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-980
4. Ozols R.F., Rubin S.C., Thomas G.M., and Robboy S.J. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R.R., Markman M., and Randall M.E. (Eds). Principles and Practices of Gynecologic Oncology. 4th edition (2005), Lippincott Williams & Wilkins, Philadelphia 895-977
5. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90 2 (2003) 390-396
6. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 (2006) 1083-1090
7. Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107 (2006) 77-85
8. Scarabelli C., Gallo A., Franceschi S., Campagnutta E., De G., Giorda G., et al. Primary cytoreductive surgery with rectosigmoid colon resection for patients with advanced epithelial ovarian carcinoma. Cancer 88 2 (2000) 389-397
9. Eisenkop S.M., Friedman R.L., and Wang H. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (1998) 103-106
10. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 103 2 (2006) 559-564
11. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., and van Dam P. Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71 (1998) 431-436
12. Hunter R.W., Alexander N.D., and Soutter W.P. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery and independent determinant of prognosis?. Am J Obstet Gynecol 166 (1992) 504-511
13. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
14. Aletti G.D., Gostout B.S., Podratz K.C., and Cliby W.A. Ovarian cancer surgical respectability: relative impact of disease, patient status, and surgeon. Gynecol Oncol 100 (2006) 33-37
15. Huober J., Meyer A., Wagner U., and Wallwiener D. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer. J Cancer Res Clin Oncol 128 (2002) 153-160
16. Steed H., Oza A.M., Murphy J., Laframboise S., Lockwood G., De Petrillo D., et al. A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer. Int J Gynecol Cancer 16 1 (2006) 47-53
17. Nelson B.E., Rosenfield A.T., and Schwartz P.E. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 11 (1993) 166-172
18. Kuhn W., Rutke S., Späthe K., Schmalfeldt B., Florak G., von Hundelshausen B., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian cancer. Cancer 92 (2001) 2585-2591
19. Schwartz P.E., Rutherford T.J., Chambers J.T., Kohorn E.I., and Thiel R.P. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecol Oncol 72 (1999) 93-99
20. Schwartz P.E., Chambers J.T., and Makuch R. Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 53 1 (1994) 33-37
21. Mazzeo F., Berlière M., Kerger J., Squifflet J., Duck L., D'Hondt V., et al. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90 (2003) 163-169
22. Vergote I.B., De Wever I., Decloedt J., Tjalma W., Van Gramberen M., and van Dam P. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Semin Oncol 27 3 Suppl 7 (2000) 31-36
23. Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S., et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 25 4 (2007) 384-389
24. Bristow R.E. Editorial: Predicting "unresectable" ovarian cancer: taking aim at a moving target. Gynecol Oncol 100 (2006) 449-450
25. Bristow R.E., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103 (2006) 1070-1076
26. Ansquer Y., Leblanc E., Clough K., Morice P., Dauplat J., Mathevet P., et al. Neoadjuvant chemotherapy for unresectable ovarian carcinoma. Cancer 91 (2001) 2329-2334
27. Bristow R.E., Eisenhauer E.L., Santillan A., and Chi D.S. Delaying the primary surgical effort for advanced ovarian cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction. Gynecol Oncol 104 2 (2007) 480-490
28. Baekelandt M. The potential role of neoadjuvant chemotherapy in advanced ovarian cancer. Int J Gynecol Cancer 13 Suppl 2 (2003) 163-168
29. Wils J., Blijham G., Naus A., Belcler C., Boschma F., Bron H., et al. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma. J Clin Oncol 4 7 (1968) 1068-1073
30. Chi D.S., Franklin C.C., Levine D.A., Askelrod F., Sabbatini P., Jarnagin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94 3 (2004) 650-654
31. Bristow R.E., Montz F.J., Lagasse L.D., Leuchter R.S., and Karlan B.Y. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 72 3 (1999) 278-287
32. Eisenkop S.M., and Spirtos N.M. Procedures required to accomplish complete cytoreduction of ovarian cancer; is there a correlation with "biological aggressiveness" and survival?. Gynecol Oncol 82 (2001) 435-441
33. Cliby W., Dowdy S., Feitoza S.S., Gostout B.S., and Podratz K.C. Diaphragm resection for ovarian cancer: technique and short-term complications. Gynecol Oncol 94 (2004) 655-660